The FDA approved Bravnetsa as the first radioligand therapy through the Abbreviated New Drug Application pathway, offering a bioequivalent alternative to Lutathera for adult patients with ...
Lyrfigtu (lirafugratinib) is approved for previously treated, unresectable, or metastatic FGFR2-altered cholangiocarcinoma based on data from the ReFocus trial.
HealthDay News — For patients receiving immune checkpoint inhibitors (ICIs), rheumatic immune-related adverse events (rh-irAEs) are usually moderate or severe, with more than one-third leading to ...
Eleven-point-four percent of patients who underwent liver transplantation for cirrhosis developed cirrhosis subsequent to transplant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results